Hey there! Welcome!
Get updated on
stem cell
stem cell
stem cell
Top Picks

calendar
30 Sep, 26
The updated guideline for stage I-III HER2-positive, HER2-negative breast cancer emphasizes endocrine therapy as the treatment foundation, with chemotherapy & targeted therapies tailored by clinical features, genomic risk & treatment tolerance.

calendar
30 Sep, 26
The guidelines for advanced gastroesophageal cancer emphasize early biomarker testing & personalized use of immunotherapy & targeted therapies, with treatment selection guided by HER2, PD-L1, CLDN18.2, & MSI/MMR status to optimize patient outcomes.

calendar
5 Oct, 26
dot
link
Diabetes Obes Metab.
  • In 192 patients with T2DM without overt HF, NT-proBNP levels increased with worsening renal function (204.3 vs 96.8 vs 62.2 pg/mL across eGFR 30-59, 60-89 & ≥90 mL/min/1.73 m²; p<0.001)
  • NT-proBNP correlated with albuminuria (uACR; r=0.31, p<0.001) but not FMD (p=0.388)
  • Older age (aOR 1.14), higher SBP (aOR 1.05), lower eGFR (aOR 0.97), & beta-blocker use (aOR 4.65) independently predicted elevated NT-proBNP.

calendar
29 Sep, 26
dot
link
BMC Infect. Dis.
  • Higher albumin-to-glucose ratio (AGR) independently reduced 30-day mortality risk by 18% (adjusted HR 0.82; P<0.001)
  • AGR showed good prognostic discrimination with an optimal cutoff of ≥5.0 (AUC 0.713); platelet count mediated only 9.24% of the AGR-mortality association
  • Patients with low AGR and low platelet count had a 4.04-fold higher crude mortality risk (HR 4.04; P<0.001)

calendar
28 Sep, 26
dot
link
Obesity Med.
  • Of the 833 adults in India with HTN &/or DM attending an NCD clinic, 70.7% had clinical obesity, highest in HTN alone (88%), with significantly elevated BMI & Conicity Index
  • Clinical obesity was independently linked with age 60-69 yrs, extended family, HTN duration >10 yrs, tobacco use, & coexistence of HTN+DM
  • Sensitivity analysis showed a lower obesity burden (50%) but retained significant predictor links.

calendar
25 Sep, 26
dot
link
J. Cos. Dermatol.
  • In this randomized trial, 156 subjects received a novel HA-based injection or established HA filler for moderate-to-severe horizontal neck wrinkles
  • At wk 4, ≥1-point improvement on the Allergan Transverse Neck Lines Scale was achieved in 83.3% vs 71.8% of patients (difference: 11.54%)
  • The novel HA filler demonstrated non-inferior efficacy, with comparable safety & no serious adverse events reported.

calendar
29 Sep, 26